State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis

被引:6
|
作者
Pelechas, Eleftherios [1 ]
Drosos, Alexandros A. [1 ]
机构
[1] Univ Ioannina, Med Sch, Dept Internal Med, Rheumatol Clin, Ioannina 45110, Greece
关键词
DMARDs; glucocorticoids; liposomal treatment; rheumatoid arthritis; treatment strategies; COBRA COMBINATION THERAPY; DOUBLE-BLIND; LONG; RECOMMENDATIONS; MANAGEMENT; RECEPTOR; TRIAL; PREDNISONE; MECHANISMS; EFFICACY;
D O I
10.1080/14656566.2022.2049238
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Glucocorticoids are steroid hormones broadly used for the treatment of several inflammatory and autoimmune diseases among other numerous indications, including rheumatoid arthritis. Areas covered For the purposes of this article, the authors have performed an extensive review of the literature to present the latest studies on glucocorticoid use in rheumatoid arthritis. They also provide the reader with their expert perspectives on future developments. Expert opinion The authors do not anticipate that glucocorticoids with be replaced in the near future by newer drugs. As such, rheumatologists should be fully aware of the possible side-effects and educate appropriately their patients to recognize and report them. Newer formulations, such as the liposomal/nanoparticle-based treatments, will result in less pronounced adverse effects, but the input of clinical experience along with the current recommendations for the glucocorticoid use will benefit both clinicians and patients with rheumatoid arthritis.
引用
收藏
页码:703 / 711
页数:9
相关论文
共 50 条
  • [21] The evolution of HIV treatment guidelines: Current state-of-the-art of ART
    Zolopa, Andrew R.
    ANTIVIRAL RESEARCH, 2010, 85 (01) : 241 - 244
  • [22] Glucocorticoid-sparing effect of first-year anti-TNFa treatment in rheumatoid arthritis (CORPUS cohort)
    Duquenne, C.
    Wendling, D.
    Sibilia, J.
    Job-Deslandre, C.
    Guillevin, L.
    Benichou, J.
    Flipo, R. M.
    Guillemin, F.
    Saraux, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : 638 - 646
  • [23] New drug therapies of rheumatoid arthritis
    Neeck, G
    MEDIZINISCHE WELT, 2000, 51 (09): : 237 - 241
  • [24] State-of-the-Art Review on Myelofibrosis Therapies
    Wang, Fuping
    Qiu, Tian
    Wang, Haitao
    Yang, Qiong
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05) : E350 - E362
  • [25] Drug delivery targets and systems for targeted treatment of rheumatoid arthritis
    Feng, Xun
    Chen, Yang
    JOURNAL OF DRUG TARGETING, 2018, 26 (10) : 845 - 857
  • [26] The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
    Wang, Dashan
    Li, Yan
    Liu, Yuan
    Shi, Guixiu
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (06) : 542 - 548
  • [27] Targeted therapies in rheumatoid arthritis: Focus on rituximab
    Teng, Y. K. O.
    Huizinga, T. W. J.
    van Laar, J. M.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04) : 325 - 333
  • [28] Potential of targeted drug delivery systems in treatment of rheumatoid arthritis
    Syed, Ayesha
    Devi, V. Kusum
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2019, 53
  • [29] State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis
    El Jammal, Thomas
    Seve, Pascal
    Gerfaud-Valentin, Mathieu
    Jamilloux, Yvan
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (02) : 205 - 218
  • [30] The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
    Garcia-Sampedro, Andres
    Gaggia, Gabriella
    Ney, Alexander
    Mahamed, Ismahan
    Acedo, Pilar
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 45